Effect of salt intake on bioavailability of mizoribine in healthy Japanese males

Drug Metabolism and Pharmacokinetics

Volumn 28, Issue 1, 2013, Pages 75-80

  Ishida, Kazuya ^a   Fukao, Miki ^a   Watanabe, Hitomi ^a   Taguchi, Masato ^a   Miyawaki, Toshio ^a   Matsukura, Hiroyoshi ^b   Uemura, Osamu ^c   Zhang, Zufei ^d   Unadkat, Jashvant D ^d   Hashimoto, Yukiya ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b Saiseikai Toyama Hospital   (Japan)

^c AICHI CHILDREN'S HEALTH AND MEDICAL CENTER   (Japan)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Bioavailability; CNT2; CNTL; Mizoribine; Nucleoside transporters; Salt intake

Indexed keywords

MIZORIBINE;

ANIMAL CELL; ARTICLE; CNT1 GENE; CNT2 GENE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; GENE; GENE EXPRESSION; GENE FREQUENCY; HUMAN; HUMAN EXPERIMENT; IC 50; INTESTINE ABSORPTION; JAPANESE; MALE; NONHUMAN; NORMAL HUMAN; SALT INTAKE; SLC28A1; URINARY EXCRETION;

EID: 84874595775     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-12-NT-043     Document Type: Article

References (24)

1. Yokota, S.: Mizoribine: mode of action and effects in clinical use. Pediatr. Int., 44: 196-198 (2002).
2. Shibasaki, T., Koyama, A., Hishida, A., Muso, E., Osawa, G., Yamabe, H., Shiiki, H., Makino, H., Sato, H., Ishikawa, I., Maeda, K., Tomita, K., Arakawa, M., Ishida, M., Sato, M., Nagase, M., Kashihara, N., Yorioka, N., Koike, T., Saito, T., Harada, T., Mitarai, T., Sugisaki, T., Nagasawa, T., Tomino, Y, Nojima, Y, Kobayashi, Y and Sakai, O.: A randomized open-label comparative study of conventional therapy versus mizoribine onlay therapy in patients with steroid-resistant nephrotic syndrome (postmarketing survey). Clin. Exp. NephroL, 8: 117-126 (2004).
3. Mizuno, K., Tsujino, M., Takada, M., Hayashi, M., Atsumi, K., Asano, K. and Matsuda, T.: Studies on Bredinin. I. Isolation, characterization and biological properties. J. Antibiot. (Tokyo), 27: 775-782 (1974).
4. Liu, D., Kobayashi, T., Nagasaka, T., Yokoyama, I., Ma, Y, Miwa, Y, Kazuya, T., Morozumi, K, Oikawa, T., Shimano, Y, Takeuchi, O., Uchida, K. and Nakao, A.: Potential value of high-dose mizoribine as rescue therapy for ongoing acute humoral rejection. Transpl Int., 18: 401-407 (2005).
5. Kusaba, R., Otubo, O., Inou, T., Tujino, M. and Ishikawa, H.: Studies on pharmacokinetics of bredinin. Jpn. J. Transplant, 17 (Suppl.): 585-593 (1982) (in Japanese).
6. Ihara, H., Shinkuma, D., Kubo, M., Miyamoto, I., Nojima, M., Koike, H., Yabumoto, H. and Ikoma, F.: Influence of bioavailability on blood level of mizoribine in kidney transplant recipients. Transplant. Proc, 28: 1321-1323 (1996).
7. Naito, T., Tokashiki, S., Mino, Y, Otsuka, A., Ozono, S., Kagawa, Y. and Kawakami, J.: Impact of concentrative nucleoside transporter 1 gene polymorphism on oral bioavailability of mizoribine in stable kidney transplant recipients. Basic Clin. Pharmacol. Toxicol, 106: 310-316 (2010).
8. Fukao, M., Ishida, K, Sakamoto, T., Taguchi, M., Matsukura, H., Miyawaki, T. and Hashimoto, Y: Effect of genetic polymorphisms of SLC28A1, ABCG2, and ABCC4 on bioavailability of mizoribine in healthy Japanese males. Drug Metab. Pharmacokinet., 26: 538-543 (2011).
9. Gray, J. Ft., Owen, R. P. and Giacomini, K M.: The concentrative nucleoside transporter family, SLC 28. Pflugers Arch., 447: 728-734 (2004).
10. Podgorska, M., Kocbuch, K and Pawelczyk, T.: Recent advances in studies on biochemical and structural properties of equilibrative and concentrative nucleoside transporters. Ada Biochim. Pol., 52: 749-758 (2005).
11. Govindarajan, R., Bakken, A. Ft., Hudkins, K L., Lai, Y, Casado, F. J., Pastor-Anglada, M., Tse, C. M., Hayashi, J. and Unadkat, J. D.: In situ hybridization and immunolocalization of concentrative and equilibrative nucleoside transporters in the human intestine, liver, kidneys, and placenta. Am. J. Physiol. Regul. Integr. Comp. Physiol, 293: R1809-R1822 (2007).
12. Patil, S. D. and Unadkat, J. D.: Sodium-dependent nucleoside transport in the human intestinal brush-border membrane. Am. J. Physiol., 272: G1314-G1320 (1997).
13. Yamamoto, T., Kuniki, K, Takekuma, Y, Hirano, T., Iseki, K. and Sugawara, M.: Ribavirin uptake by cultured human choriocarcinoma (BeWo) cells and Xenopus laevis oocytes expressing recombinant plasma membrane human nucleoside transporters. Eur J. Pharmacol, 557: 1-8 (2007).
14. +-nucleoside purine (Nl) transporter. Pharm. Res., 15: 950-952 (1998).
15. Ishida, K, Takaai, M., Yotsutani, A., Taguchi, M. and Hashimoto, Y: Membrane transport mechanisms of mizoribine in the rat intestine and human epithelial LSI80 cells. Biol. Pharm. Bull, 32: 741-745 (2009).
16. Ishida, K, Takaai, M., Yotsutani, A., Yokota, A., Sakamoto, T, Taguchi, M., Matsukura, H, Miyawaki, T and Hashimoto, Y: Mechanisms responsible for different rates of uptake of mizoribine and ribavirin by human epithelial LSI80 cells. Jpn. J. Pharm. Health Care Sci., 36: 900-905 (2010).
17. Lai, Y, Bakken, A. H. and Unadkat, J. D.: Simultaneous expression of hCNTl-CFP and hENTl-YFP in Madin-Darby canine kidney cells. Localization and vectorial transport studies. J. Biol. Chem., 277: 37711-37717 (2002).
18. Ward, J. L., Sherali, A., Mo, Z. P. and Tse, C. M.: Kinetic and pharmacological properties of cloned human equilibrative nucleoside transporters, ENT1 and ENT2, stably expressed in nucleoside transporter-deficient PK15 cells. ENT2 exhibits a low affinity for guanosine and cytidine but a high affinity for inosine. J. Biol. Chem., 275: 8375-8381 (2000).
19. Honda, M., Itoh, H, Suzuki, T. and Hashimoto, Y: Population pharmacokinetics of higher-dose mizoribine in healthy male volunteers. Biol. Pharm. Bull, 29: 2460-2464 (2006).
20. Schiller, L. R.: Small Intestine. Philadelphia, Current Medicine, Inc., 1997.
21. Baldwin, S. A., Beal, P. R., Yao, S. Y, King, A. E., Cass, C. E. and Young, J. D.: The equilibrative nucleoside transporter family, SLC29. Pflugers Arch., 447: 735-743 (2004).
22. He, F. J., Jenner, K. H. and Macgregor, G. A.: WASH-world action on salt and health. Kidney Int., 78: 745-753 (2010).
23. Cianciaruso, B., Bellizzi, V., Minutolo, R., Tavera, A., Capuano, A., Conte, G. and De Nicola, L.: Salt intake and renal outcome in patients with progressive renal disease. Miner. Electrolyte Metab., 24: 296-301 (1998).
24. He, F. J., Marciniak, M., Visagie, E., Markandu, N. D., Anand, V., Dalton, R. N. and MacGregor, G. A.: Effect of modest salt reduction on blood pressure, urinary albumin, and pulse wave velocity in white, black, and Asian mild hypertensives. Hypertension, 54: 482-488 (2009).